Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IFRX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontane… NCT06555328 · Chronic Urticaria, Idiopathic, Hidradenitis CSU lower dose treatment, CSU high dose treatment | IFRX InflaRx GmbH | Phase 2 | Terminated | 73 | Jan 22, 2026 | Registry ↗ |
| Nov 4, 2025 | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum NCT05964413 · Pyoderma Gangrenosum vilobelimab, Placebo | IFRX InflaRx GmbH | Phase 3 | Terminated | 54 | Jul 11, 2025 | Registry ↗ |
| Feb 11, 2025 | Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Me… NCT04812535 · SCC - Squamous Cell Carcinoma of Skin Vilobelimab, Vilobelimab + pembrolizumab combination therapy | IFRX InflaRx GmbH | Phase 2 | Terminated | 30 | Jun 4, 2024 | Registry ↗ |
| Sep 14, 2023 | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum NCT03971643 · Pyoderma Gangrenosum vilobelimab | IFRX InflaRx GmbH | Phase 2 | Completed | 19 | Jan 3, 2022 | Registry ↗ |
| Jun 5, 2023 | Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia NCT04333420 · Severe COVID-19 Pneumonia IFX-1 + BSC, BSC | IFRX InflaRx GmbH | Phase 2/3 | Completed | 399 | Oct 31, 2021 | Registry ↗ |
| Aug 25, 2022 | Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopi… NCT03895801 · Granulomatosis With Polyangiitis (GPA), Microscopic Polyang… IFX-1, Placebo-IFX-1 | IFRX InflaRx GmbH | Phase 2 | Completed | 57 | Apr 14, 2021 | Registry ↗ |
| May 26, 2022 | Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA NCT03712345 · Granulomatosis With Polyangiitis (GPA), Microscopic Polyang… IFX-1 low dose, IFX-1 high dose | IFRX InflaRx GmbH | Phase 2 | Terminated | 20 | Sep 10, 2020 | Registry ↗ |
| Apr 8, 2021 | Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) NCT03487276 · Hidradenitis Suppurativa (HS) IFX-1, Placebo | IFRX InflaRx GmbH | Phase 2 | Completed | 179 | May 27, 2019 | Registry ↗ |
| Sep 19, 2017 | Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa NCT03001622 · Hidradenitis Suppurativa IFX-1 | IFRX InflaRx GmbH | Phase 2 | Completed | 12 | Jul 2017 | Registry ↗ |
| Feb 15, 2017 | Studying Complement Inhibition in Complex Cardiac Surgery NCT02866825 · Systemic Inflammatory Response Syndrome, C.Surgical Procedu… IFX-1, Placebo | IFRX InflaRx GmbH | Phase 2 | Completed | 116 | Dec 2016 | Registry ↗ |
| Apr 25, 2016 | Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction NCT02246595 · Severe Sepsis, Septic Shock CaCP29, Placebo | IFRX InflaRx GmbH | Phase 2 | Completed | 72 | Dec 2015 | Registry ↗ |
11 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:45 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances